Results 101 to 110 of about 302,595 (156)
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study [PDF]
Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure ...
Limia, Aurora +37 more
core +1 more source
The need for pre-emptive control strategies for mpox in Asia and Oceania
Infectious Disease ModellingIntroduction: The transmission dynamics of the recent mpox outbreak highlights the lack of infrastructure available to rapidly respond to novel STI outbreaks, of which Asia and Oceania remains particularly susceptible. Here, we simulate outbreaks in this
Gregory Gan +4 more
doaj +1 more source
Preemptive Mpox Vaccine Deployment: Aligning Strategy With Reality
The Journal of Infectious DiseasesTO THE EDITOR—We appreciate Tsagkaris and colleagues’ commentary on our study, which draws attention to key aspects of mpox vaccine deployment in Greece and its broader relevance in the global context. We fully agree that logistical coordination, resilient infrastructure, and public trust are essential to an effective and equitable mpox ...
Sung-mok Jung +6 more
openaire +4 more sources
Target Trial Emulation of the Modified Vaccinia Ankara-Bavarian Nordic Vaccine for Pre-Exposure Mpox Prevention in At-Risk Populations. [PDF]
Background: The MVA-BN vaccine is considered effective for preventing mpox in key populations, based on observational studies, though no randomized trials have yet confirmed its effectiveness. Observational studies published to date rely on retrospective
Suñer, Clara +53 more
core +1 more source
Breakthrough mpox despite two‐dose vaccination
Medical Journal of Australia, 2023 Madhara N Weerasinghe +4 more
openaire +2 more sources
Mpox-Specific Immune Responses Elicited by Vaccination or Infection in People With HIV
11101119In the recent mpox outbreak, people with human immunodeficiency virus (PWH) were at high risk both for contracting infection and for a more severe disease course. We studied cellular and humoral immune responses elicited by mpox infection (n = 5;
Conca, Raffaele +15 more
core +1 more source
Updated January 31, 2023Who should use this information? Health departments, public health partners, and groups working with populations most affected by mpox.What is this page about?
core +2 more sources
Background: The Mpox outbreak, caused by Monkeypox virus (MPXV), underscores the need for a serological assay to assess Mpox immunity. Modified Vaccinia Ankara (MVA) vaccine, an attenuated vaccinia virus (VACV), is authorised for Mpox prevention.
Gurvin Saini (14264138) +18 more
core +2 more sources
Information on Mpox vaccine acceptability and uptake from cross-sectional surveys [PDF]
Mpox-05-Delaney-508 ...
core